COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea.

Citation metadata

From: PLoS ONE(Vol. 16, Issue 10)
Publisher: Public Library of Science
Document Type: Report
Length: 4,108 words
Lexile Measure: 1450L

Document controls

Main content

Abstract :

Background Given the rapid increased in confirmed coronavirus disease 2019 (COVID-19) and related mortality, it is important to identify vulnerable patients. Immunocompromised status is considered a risk factor for developing severe COVID-19. We aimed to determine whether immunocompromised patients with COVID-19 have an increased risk of mortality. Method The groups' baseline characteristics were balanced using a propensity score-based inverse probability of treatment weighting approach. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated for the risks of in-hospital mortality and other outcomes according to immunocompromised status using a multivariable logistic regression model. We identified immunocompromised status based on a diagnosis of malignancy or HIV/AIDS, having undergone organ transplantation within 3 years, prescriptions for corticosteroids or oral immunosuppressants for [greater than or equal to]30 days, and at least one prescription for non-oral immunosuppressants during the last year. Results The 6,435 COVID-19 patients ([greater than or equal to]18 years) included 871 immunocompromised (13.5%) and 5,564 non-immunocompromised (86.5%). Immunocompromised COVID-19 patients were older (60.1±16.4 years vs. 47.1±18.7 years, absolute standardized mean difference: 0.738). The immunocompromised group had more comorbidities, a higher Charlson comorbidity index, and a higher in-hospital mortality rate (9.6% vs. 2.3%; p Conclusions Immunocompromised status among COVID-19 patients was associated with a significantly increased risk of mortality.

Source Citation

Source Citation   

Gale Document Number: GALE|A677537320